Name | Type | Posted | Actions |
|---|---|---|---|
A19 Solicitation - 75D30125R00065.pdf | Jan 17, 2025 | ||
Subcontracting Plan Submission Link | LINK | Jan 17, 2025 | |
A19 Vaccine Order Limitation Chart.docx | DOCX | Jan 16, 2025 | |
A19 Authorized Distributor of Record (ADR) Agreement.docx | DOCX | Jan 16, 2025 | |
A19 Solicitation - 75D30125R00065.pdf | Jan 16, 2025 |
FY25 Vaccines for Children
Contact and place of performance
James Sprigler
Atlanta, GA 30341
USA
The Centers for Disease Control and Prevention (CDC) awards contracts to the manufacturers of pediatric vaccines for the purchase of standard commercial pediatric vaccines. Vaccines are one of the most cost-effective ways to prevent disease and reduce healthcare costs. The Vaccine for Children (VFC) program, established pursuant to Section 13631 of the Omnibus Budget Reconciliation Act of 1993 (OBRA 93), guarantees f...
View moreThe Centers for Disease Control and Prevention (CDC) Office of Acquisition Services issued solicitation 75D30125R00065 to procure standard commercial pediatric vaccines from manufacturers. This requirement supports the Vaccines for Children (VFC) program, established under the Omnibus Budget Reconciliation Act of 1993, to provide federal support for the purchase and supply of vaccines to states for a defined group of eligible children aged 18 or younger. The program serves children who are Medicaid-eligible, uninsured, American Indian or Alaska Native, or underinsured when receiving immunizations at Federally-qualified health centers or rural health clinics.
Qualified offerors must meet the definition of a manufacturer as specified in 42 U.S.C. 1396s, which includes entities that manufacture, import, process, or distribute pediatric vaccines under their own label. The resulting contracts allow the CDC to utilize VFC and Section 317 funds to acquire vaccines at prices below commercial marketplace rates. Additionally, awardees may choose to purchase further quantities for non-federally eligible children using state and local funds to ensure broader immunization coverage and effective public health practices.
This combined synopsis/solicitation is classified under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC 6505 for Drugs and Biologicals. Performance is located in Atlanta, Georgia, and the response deadline is January 30, 2025. The solicitation includes five attachments, featuring a vaccine order limitation chart, an authorized distributor of record agreement, and instructions for subcontracting plan submissions. James Sprigler serves as the primary point of contact for this requirement.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.